Table 2 Acalabrutinib (ACP-196) for solid tumors
From: Acalabrutinib (ACP-196): a selective second-generation BTK inhibitor
Agents | Diseases | Phase | NCT |
|---|---|---|---|
ACP-196 | Glioblastoma multiforme | Phase 1/2 | NCT02586857 |
ACP-196 Pembrolizumab | Urothelial carcinoma | Phase 2 | NCT02351739 |
ACP-196 Pembrolizumab | Non-small-cell lung cancer | Phase 2 | NCT02448303 |
ACP-196 Pembrolizumab | Head and neck Squamous cell carcinoma | Phase 2 | NCT02454179 |
ACP-196 Pembrolizumab | Ovarian cancer | Phase 2 | NCT02537444 |
ACP-196 Pembrolizumab | Pancreatic cancer | Phase 2 | NCT02362048 |
ACP-196 Nab-paclitaxel Gemcitabine | Pancreatic cancer | Phase 2 | NCT02570711 |